Clinical Trial Update: A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update of a recombinant anti-IL-1β monoclonal antibody for acute gout in Chinese participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• recombinant anti-IL-1β humanized monoclonal antibody (anti-IL-1β monoclonal antibody)

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Acute Gout | Phase 3 | Status: UNKNOWN